|
Part I 參考文獻
1. Coffey, S. Rodd’s Chemistry of Carbon Compound, 2nd. M. Sainsbury, Vol. IV G. Chapter 31 (1978).
2. Steldt and Chen, J. Am. Pharm. Assoc., 32, 107-108 (1943).
3. S. Goodwin, A. F. Smith, A. A. Velasquez and E. C. Horning. Alkaloids of Lunasia amara Blanco. Isolation Studies, J. Am. Chem. Soc., 81, 6209-6212 (1959).
4. (a) Rapport, H.; Holden, K. G. J. Am. Chem. Soc. 1960, 82, 4395-4404. (b) Razzakova, D. M.; Bessonova, I. A. S. Yu. Khim. Prir. Soedin. 1972, 6, 755-759. (c) Tillequin, F.; Koch, M.; Sevent, T. Planta Medica. 1980, 39, 383-387. (d) Rizvi, S. H.; Kapil, R. S.; Shoeb, A. J. Nat. Prod. 1985, 48, 146. (e) Sondheirner, F.; Meisels, A. J. Org. Chem. 1958, 23, 762-763. (f) Johnstone, R.; Price, J. R.; Todd, A. R. Aust. J. Chem. 1958, 11, 562-576. (g) Kind, F. A.; Romo, J.; Rosenkranz G.; Sondheimer, F. J. Chem. Soc. 1956, 4163. (h) Boyl, D. R.; Grundon, M. F. J. Chem. Soc. 1970, 556-558. (i) Ha-Huy-Ke; Martin, L.; Johannes, R. Phytochemistry, 1970, 9, 2199-2208. (j) Toshikazu, Y.; Natsuki, K.; Katsura, M. Agric. Biol. Chem. 1977, 41, 1263-1268. (k) Price, J. R.; Todd, A. R. Aust. J. Chem. 1968, 21,445-448. (l) Arthur, H. R.; Cheunq, H. T. Aust. J. Chem. 1960, 13, 510. (m) Ulubelen, A.; Terem, B. E.; Tuzlaci, K. F.; Cheng, Y. C. Aust. J. Chem. 1965, 18, 430. (n) Wu, T. S. Phytochemistry, 1987, 26, 873-875.
5. Donnelly, W. J.; Grundon, M. F. Quinoline Alkaloids. Part XII. Alkaloids and Coumarines of Orixa japonica thunb. Identification of a New Quinoline Alkaloid, Orixinone. J. Chem. Soc. Perkin Trans 1, 1972, 2116-2118.
6. Ito, A.; Shamon, L. A.; Yu, B.; Mata-Greenwood, E.; Lee, S. K.; van Breemen, R. B.; Mehta, R. G.; Farnsworth, N. R.; Fong, H. S.; Pezzuto, J. M.; Kinghorn, A. D. Antimutagenic Constituents of Casimiroa edulis with Potential Cancer Chemopreventive Activity. J. Agric. Food Chem. 1998, 46, 3509-3516.
7. Grundon, M. F.; Harrison, D. M.; Sypropoulos, C. G. Biosynthesis of Aromatic Isoprenoids. Part II. Aromatic Hydroxylation in the Biosynthesis of the Furoquinoline Alkaloids, Skimmianine, Evoxine and Choisyine. J. Chem. Soc. Perkin Trans. 1, 1974, 2181-2184.
8. Blaschke-Cobet M.; Luckner, M. Zur Biosynthese des Graveolins bei Ruta angustifolia. Phytochemistry. 1973, 12, 2393-2398.
9. Goodwin, S.; Smith, A. F.; Velasquez, A. A.; Horning, E. C. Alkaloids of Lunasia amara Blanco. Isolation Studies. J. Am. Chem. Soc. 1959, 81, 6209-6212.
10. Oliveira, F. M.; Sant'ana, A. E. G.; Conserva, L. M.; Maia, J. G. S.; Guilhon, G. M. P. Phytochemistry, 1996, 41, 647-650.
11. Toshikazu Yajima, Natsuki Kato and Katsura Munakata, Isolation of Insect Anti-feeding Principles in Orixa japonica thumb. Agri. Biol. Chem. 1977, 41, 1263-1268.
12. Xia, Y.; Yang, Z. Y.; Xia, P.; Bastow, K. F.; Taxhibana, Y.; Kuo, S. C.; Hamel, E.; Hackl, T.; Lee, K. H. Antitumor Agents. 181. Synthesis and Biological Evaluation of 6,7,2',3',4'-Substituted -1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a New Class of Antitmitotic Antitmor Agents. J. Med. Chem. 1998, 41, 1155-1162.
13. Kuo, S. C.; Lee, H. Z.; Juang, J. P.; Lin, Y. T.; Wu, T. S.; Chang, J. J.; Lendnicer, D.; Kenneth, P. D.; Lin, C. M.; Hamel E.; Lee, K. H. Synthesis and Cytotoxicity of 1,6,7,8-Substituted 2-(4'-substituted phenyl)-4-quinolones and Related Compounds: Identification as Antimitotic Agents Iinteracting with Tubulin. J. Med. Chem. 1993, 36, 1146-1156.
14. Li, L.; Wang, H. K.; Kuo, S. C.; Wu, T. S.; Lendnicer, D.; Lin, C. M.; Hamel, E.; Lee, K. H. Antitumor Agents. 150. 2',3',4',5',5,6,7-Substituted 2-phenyl-4-quinolones and Related Compounds: Their Synthesis, Cytotoxicity, and Inhibition of Tubulin Polymerization. J. Med. Chem. 1994, 37, 1126-1135.
15. Li, L.; Wang, H. K.; Kuo, S. C.; Wu, T. S.; Mauger, A. A.; Lin, C. M.; Hamel, E.; Lee, K. H. Antitumor Agents. 155. Synthesis and Biological Evaluation of 3',6,7- Substituted 2-phenyl-4-quinolones as Micrctubule Agents. J. Med. Chem. 1994, 37, 3400-3407.
16. Neil, G. L.; Li, L. H.; Buskirk, H. H.; Moxley, T. E. Antitumor Effects of the Antispermatogenic Agent, 2,3-Dihydro-2-(1-naphthyl)-4-(1H)-quinazolinone. Cancer Chemother. 1972, 56, 163-173.
17. Yale, H. J.; Kalkstein, M. Substituted 2,3-dihydro-4-(lH) quinazolinones. A New Class of Inhibitors of Cell Multiplication. J. Med. Chem. 1967, 10, 334-336.
18. Chen, K.; Kuo, S. C.; Hsieh, M. C.; Mauger, A.; Lin, C. M.; Hamel, E.; Lee, K. H. Antitumor Agents. 174. 2,3,4,5,6,7-Substituted 2-phenyl-1,8-naphthyridin-4-ones: Their Synthesis, Cytotoxicity, and Inhibition of Tubulin Polymerization. J. Med. Chem. 1997, 40, 2266-2275.
19. Chen, K.; Kuo, S. C.; Hsieh, M. C.; Mauger, A.; Lin, C. M.; Hamel, E.; Lee, K. H. Antitumor Agents. 178. Synthesis and Biological Evaluation of Substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as Antitumor Agents that Inhibit Polymeriza- tion. J. Med. Chem. 1997, 40, 3049-3056.
20. Jiang, J. B.; Hesson, D. P.; Dusak, B. A.; Dexter, D. L.; Kang, G. J.; Hamel, E. Synthesis and Bbiological Evaluation of 2-Styryl-quinazolin-4(3H)-ones, a New Class of Antimitotic Anticancer Agents which Inhibit Tubulin Polymerization. J. Med. Chem. 1990, 30, 1721-1728.
21. Lee, H. Z.; Lin, W. C.; Yeh, F. T.; Wu, C. H. 2-Phenyl-4-quinolone Prevents Serotonin-induced Increases in Endothelial Permeability to Albumin. Eur. J. Pharmacol. 1998, 394, 205-213.
22. Wang, J. P.; Raung, S. L.; Huang, L. J.; Kuo, S. C. Involvement of Cyclic AMP Generation in the Inhibition of Respiratory Burst by 2-Phenyl-4-qunolone (YT-1) in Rat Neutrophils. Biochem. Pharmacol. 1998, 56, 1505-1514.
23. Hsieh, M. C.; Huang, L. J.; Lee, K. H.; Wu, T. S.; Chen, S. C.; Teng, C. M.; Kuo, S. C. Synthesis and Antiplatelet Activity of 3,5,6,7,8,2’,3’ and 4’-Monosubstituted 2-phenyl-4-quinolones. Chin. Pharm. J. 1998, 50, 67-80.
24. Hsieh, M. C.; Huang, L. J.; Wu, T. S.; Lee, K. H.; Teng, C. M.; Kuo, S. C. Synthesis and Antiplatelet Activity of 3,5,6,7,8,2’,3’and 4’-Disubstituted 2-phenyl-4-quinolones. Chin. Pharm. J. 1998, 50, 277-288.
25. Liebman, M. N. Molecular Modeling of Microtubule Inhibitors and the Colchicine Binding Site on Tubulin. Ann. N. Y. Acad. Sci. 1986, 466, 788-790.
26. Guenard, D.; Gueritte-Voegelein, F.; Dubois, J.; Potier, P. Structure-Activity Relationships of Taxol and Taxotere Analogues. J. Natl. Cancer Inst. Monogr. 1993, 15, 79-82.
27. ter Haar, E.; Rosenkranz, H. S.; Hamel, E.; Day, B. W. Computational and Molecular Modeling Evaluation of the Structural Basis for Tubulin Polymerization Inhibition by Colchicine Site Agents. Bioorg. Med. Chem. 1996, 4, 1659-1671.
28. Moyna, G.; Williams, H. J.; Scott, A. I.; Ringel, I.; Gorodetsky, R.; Swindell, C. S. Conformational Studies of Paclitaxel Analogs Modified at the C-2' Position in Hydrophobic and Hydrophilic Solvent Systems. J. Med. Chem. 1997, 40, 3305-3311.
29. Zhu, Q.; Guo, Z.; Huang, N.; Wang, M.; Chu, F. Comparative Molecular Field Analysis of a Series of Paclitaxel Analogues. J. Med. Chem. 1997, 40, 4319-4328.
30. Aleksandrzak, K.; McGown, A. T.; Hadfield, J. A. Antimitotic Activity of Diaryl Compounds with Structural Features Resembling Combretastatin A-4. Anticancer Drugs 1998, 9, 545-550.
31. Giannakakou, P.; Gussio, R.; Nogales, E.; Downing, K. H.; Zaharevitz, D.; Bollbuck, B.; Poy, G.; Sackett, D.; Nicolaou, K. C.; Fojo, T. A Common Pharmacophore for Epothilone and Taxanes: Molecular Basis for Drug Resistance Conferred by Tubulin Mutations in Human Cancer Cells. Proc. Natl. Acad. Sci. 2000, 97, 2904-2909.
32. He, L.; Jagtap, P. G.; Kingston, D. G.; Shen, H. J.; Orr, G. A.; Horwitz, S. B. A Common Pharmacophore for Taxol and the Epothilones Based on the Biological Activity of a Taxane Molecule Lacking a C-13 Side Chain. Biochemistry 2000, 39, 3972-3978.
33. Brown, M. L.; Rieger, J. M.; Macdonald, T. L. Comparative Molecular Field Analysis of Colchicine Inhibition and Tubulin Polymerization for Combretastatins Binding to the Colchicine Binding Site on beta-Tubulin. Bioorg. Med. Chem. 2000, 8, 1433-1441.
34. Bai, R.; Covell, D. G.; Pei, X. F.; Ewell, J. B.; Nguyen, N. Y.; Brossi, A.; Hamel, E. Mapping the Binding Site of Colchicinoids on beta-Tubulin. 2-Chloroacetyl-2-demethylthiocolchicine Covalently Reacts Predominantly with Cysteine 239 and Secondarily with Cysteine 354. J. Biol. Chem. 2000, 275, 40443-40452.
35. Martello, L. A.; LaMarche, M. J.; He, L.; Beauchamp, T. J.; Smith, A. B.; Horwitz, S. B. The Relationship between Taxol and (+)-Discodermolide: Synthetic Analogs and Modeling Studies. Chem. Biol. 2001, 8, 843-855.
36. Barbier, P.; Gregoire, C.; Devred, F.; Sarrazin, M.; Peyrot, V. In vitro Effect of Cryptophycin 52 on Microtubule Assembly and Tubulin: Molecular Modeling of the Mechanism of Action of a New Antimitotic Drug. Biochemistry 2001, 40,13510-13519.
37. Zhang, S. X.; Feng, J.; Kuo, S. C.; Brossi, A.; Hamel, E.; Tropsha, A.; Lee, K.H. Antitumor Agents. 199. Three-Dimensional Quantitative Structure-Activity Relationship Study of the Colchicine Binding Site Ligands Using Comparative Molecular Field Analysis. J. Med. Chem. 2000, 43, 167-176.
38. Wermuth, C. G. Three-dimensional Quantitative Structure-Activity Relationship, The Practice of Medicinal Chemistry. 1996, P459-483.
39. Wold, S.; Johansson, E.; Cocchi, M. PLS-Partial Least-Square Projections to Latent Structures. In Kubinyi, H. 3D QSAR in Drug Design. Theory, Methods and Applications. 1993, p523-550. Escom, Leiden.
40. Elderfield, R. C.; Gensler, W. J.; Bembry, T. H.; Kremer, C. B.; Head, J. D.; Brody, F.; Frohardt, R. Synthesis of 2-Phenyl-4-chloroquinolines. J. Am. Chem. Soc. 1946, 68, 1272-1275.
41. Kappe, C. O.; Kollenz, G.; Wentrup, C. A Nitrile Oxide Transformation. J. Chem. Soc. Chem. Commun. 1992, 485-486.
42. El-Nabi, H. A. Abd; Kollenz, G. Monatsh. Chem. 1997, 128, 381-388.
43. Jung, J. C.; Jung, Y. J.; Park, O. S. Synthesis of 4-Hydroxyqunolin-2(1H)-one Analogues and 2-Substituted Quinolone Derivatives. J. Heterocycl. Chem. 2001, 38, 61-67.
44. 韓銳主編，腫瘤化學預防及藥物治療，北京醫科大學－中國協和醫科大學聯合出版社，1991
45. Correia, J. J.; Beth, A. H.; Williams, R. C. Jr. Tubulin Exchanges Divalent Cations at Both Guanine Nucleotide-Binding Sites. J. Biol. Chem. 1988, 263, 10681-10686.
46. Lodish, H.; Berk, A.; Zipursky, S. L.; Matsudaira, P.; Baltimore, D.; Darnell, J. E. Molecular Cell Biology, 4th ed. W. H. Freeman and Company, New York 2000.
47. Rieder, C. L.; Alexander, S. P. Kinetochores Are Transported Poleward Along a Single Astral Microtubule during Chromosomes Attachment to the Spindle in Newt Lung Cells. J. Cell Biol. 1990, 110, 81-95.
48. Downing, K. H.; Nogalest, E.; Tubulin Structure: Insights into Microtubule Properties and Functions. Curr. Opin. Struct. Biol. 1998, 8, 785-791.
49. Manfriedi, J. J.;Horwitz, S. B. Taxol: An Antimitotic Agent with a New Mechanism of Action. Pharmacol. Ther. 1984, 25, 83-125.
50. Batra, J. K.; Powers, L. J.; Hess, F. D.; Hamel, E. Derivatives of 5,6-Diphenylpyridazin-3-one: Synthetic Antimitotic Agents which Interact with Plant and Mammalian Tubulin at a New Drug-Binding Site. Cancer Res. 1986, 46, 1889-1893.
51. Liu, Z. L. Immunofluorescent Studies on Cytoplasmic Microtubule Complex (CMTC) of Vero Cells Treated with 5,6-Diphenylpyridazin-3-one Derivatives. Zhongguo Yi Xue Ke Xue Yuan Xue Bao.1990, 12, 213-216.
52. http://www.cellsalive.com/ell_cycle.htm
53. http://www.chembio.uoguelph.ca/educmat/chm736/cycletx.htm
54. Aggarwal. Tumor Necrosis Factors Receptor Associated Signalling Molecules and Their Role in Activation of Apoptosis, JNK and NF-kappaB. Ann. Rheum. Dis. 2000, 59, 6-16.
55. Hsu, Xiong, and Goeddel. The TNF Receptor 1-Associated Protein TRADD Signals Cell Death and NF-kB Activation. Cell. 1995, 85, 495-504.
56. Dyke and Montana. Update on the Therapeutic Potential of PDE4 Inhibitors. Expert Opin. Investig. Drugs. 2002, 11, 1-13.
57. Niwa, M.; Hara, A.; Kanamori, Y.; Matsuno, H.; Kozawa, O.; Yoshimi, N.; Mori, H.; Uematsu, T. Inhibition of Tumor Necrosis Factor-α-induced Neutrophil Apoptosis by Cyclic AMP: Involvement of Caspase Cascade. Eur. J. Pharmacol. 1999, 371, 59-67.
58. Hofman, F. M.; Hinton, D. R.; Johnson K.; Merrill, J. E. Tumor Necrosis Factor Identified in Multiple Sclerosis Brain. J. Exp. Med. 1995, 170, 607-612.
59. Meda, L.; Cassatella, M. A.; Szendrei, G. I.; Otvos, L. Jr.; Baron, P.; Villalba, M.; Ferrari, D.; Rossi, F. Activation of Microglial Cells by β-Amyloid Protein and Interferon-γ. Nature 1995, 374, 647-650.
60. Pruzanski, W.; Kennedy, B. P.; Bosch, H. van den; Stefanski, E.; Vadas, P. Microtubule Depolymerization Selectively Down-regulates the Synthesis of Proinflammatory Secretory Nonpanreatic Phospholipase A2. Lab. Invest. 1997, 76, 171-178.
61. Ishizaka, T.; Ishizaka, K.; Tomioka, H. Release of Histamine and Slow Reacting Substance of Anaphylaxis (SRS-A) by IgE-anti-IgE Reactions on Monkey Mast Cells. J. Immunol. 1972, 108, 513-520.
62. Austen, K. F. Biologic Implications of Structural and Functional Characteristics of the Chemical Mediators of Immediate Type Hypersensitivity. Harvey Lect. 1979, 73, 93-161.
63. Adams, G. K.; Lichtenstein, L. M. In vitro Studies of Antigen-induced Broncho Spasm: Effect of Antihistamine and SRS -A antagonist on Response to Sensitized Guinea Pig and Human Airways to Antigen. J. Immunol. 1979, 122, 555-562.
64. Schwartz, L. B.; Austen, K. F. Structural and Function of the Chemical Mediators of Mast Cells. Prog. Allergy 1984, 34, 271-321.
65. Semb, A. G.; Vage, J.; Mjos, O. D. Oxygen Free Radical Producing Leukocytes Cause Flinctional Depression of Isolated Rat Hearts: Role of Leukotrienes. J. Mol. Cell. Cardiol. 1990, 22, 555-563.
66. Harman, D.; Piette, L. H. Free Radical Theory of Aging: Free Radical Reactions in Serum. J. Gerontol. 1966, 21, 560-565.
67. Parks, D. A.; Granger, D. N. Ischemia Induced Vascular Changes: Role of Xanthine Oxidase and Hydroxyl Radicals. Am. J. Physiol. 1983, 245, G285-G289.
68. McCord, J. M. Oxygen-derived Free Radicals in Postischemic Tissue Injury. N. Engl. J. Med. 1985, 312, 159-163.
69. Kvietys, P. R.; Smith, S. M.; Grisham, M. B.; Manaci, E. A. 5-Aminosalicylic Acid Protects against Ischemia/Reperfusion-Induced Gastric Bleeding in the Rat, Gastroenterology 1988, 94, 733-738.
70. McCord, J. M. Free Radicals and Inflammation: Protection of Synovial Fluid by Superoxide Dismutase. Science 1974, 185, 529-531.
71. Allen, R. E.; Blake, D. R.; Nazhat, N. B.; Jones, P. Superoxide Radical Generation by Inflamed Human Synovium after Hypoxia. Lancet 1989, 2, 282-283.
72. Craven, P. A.; Pfanstiel, J.; Saito, R.; DeRubertis, F. R. Action of Sulfasalazine and 5-Aminosalicylic Acid as Reactive Oxygen Scavengers in the Suppression of Bile Acid-induced Increases in Colonic Epithelial Cell Loss and Proliferative Activity. Gastroenterology 1987, 92, 1998-2008.
73. Grisham, M. B.; Granger, D. N. Neutrophil-mediated Mucosal Injury: Role of Reactive Oxygen Metabolites. Dig. Dis. Sci. 1988, 33 (3 Suppl), 6S-15S.
74. Weissmann, G.; Smolen, J. E.; Korzhak, H. M. Release of Inflammatory Mediators from Stimulated Neutrophils. N. Engl. J. Med. 1980, 303, 27-34.
75. Davies, M.; Barrett, A. J.; Travis, J.; Sanders, E.; Coles, G. A. The Degradation of Human Glomerular Basement Membrane with Purified Lysosomal Proteinases: Evidence for the Pathogenetic Role of the Polymorphonuclear Leukocyte in Glomerulonephritis. Clin. Sci. Mol. Med. 1978, 54, 233-240.
76. Menninger, H.; Putzier, R.; Mohr, W.; Weissinghage, D.; Tillmann, K. Granulocyte Elastase at the Site of Cartilage Erosion by Rheumatoid Synovial Tissue. J. Rheumatol. 1980, 39, 145-156.
77. Saklatvala, J.; Barrett, A. J. Identification of Proteinases in Rheumatoid Synovium: Detection of Leukocyte Elastase, Cathepsin G and Another Serine Proteinase. Biochem. Biophys. Acta. 1980, 615, 167-l77.
78. Burde, R.; Seifert, R.; Buschauer, A.; Schultz, G. Histamine Inhibits Activation of Human Neutrophils and HL-60 Leukemic Cells via H2 Receptors. Nauny-Schmiedeberg's Arch. Pharmacol. 1989, 340, 67l-678.
79. Iannone, M. A.; Wolberg, G.; Zimmerman, T. P. Chemotatic Peptide Induces cAMP Elevation in Human Neutrophils by Amplification of the Adenylyl Cyclase Response to Endogenously Produced Adenosine. J. Biol. Chem. 1989, 264, 20177-20180.
80. Nielson, C. P.; Vestal, R. E. Effects of Adenosine on Polymorphonuclear Leukocyte Function, Cyclic 3',5'-Adenosine Monophosphate, and Intracellular Calcium. Br. J. Pharmacol. 1989, 97, 882-888.
81. Akinshola, B. E.; Verma, P.S.; Taylor, R. E. Effect of in vitro Incorporation of Prostanoid Precursors, Superoxide Radical and Hydrogen Peroxide on Platelet Function. Thromb. Res. 1995, 79, 343-351.
82. Fredholm, B. B.; Zhang, Y.; Van der Ploleg, I. Adenosine A2A Receptors Mediate the Inhibitory Effect of Adenosine of Formyl-Met-Leu-Phe- Stimulated Respiratory Burst in Neutrophil Leukocyte. Nauny-Schmiedeberg's Arch. Pharmacol. 1996, 354, 262-267.
83. Laudanna, C.; Campbell, J. J.; Butcher, E. C. Elevation of Intracellular cAMP Inhibits RhoA Activation and Integrin-dependent Leukocyte Adhesion Induced by Chemoattractants. J. Biol. Chem. 1997, 272, 24141-24144.
84. VanUffelen, B. E.; de-Koster, B. M.; Elferink, J. G. Interaction of Cyclic GMP and Cyclic AMP during Neutrophil Migration Involvement of Phosphodiesterase Type III. Biochem. Pharmacol. 1998, 56, 1061-1063.
85. Armstrong, R. A. Investigation of the Inhibitory Effects of PGE2 and Selective EP Agonists on Chemotaxis of Human Neutrophils. Br. J. Pharmacol. 1995, 116, 2903-2908.
86. Wies, H. The Inhibitory Effect of Prostaglandin E2 on Rat Neutrophil Aggregation. J. Leukoc. Biol. 1996, 60, 480-486.
87. Gutteridge, J. M.; Halliwell, B. The Measurement and Mechanism of Lipid Peroxidation in Biological System. Trends. Biochem. Sci. 1990, 15, 129-135.
88. Mallat, M.; Chamak, B. Brain Macrophages: Neurotoxic or Neurotrophic Effector cells. J. Leukoc. Biol. 1994, 56, 416-422.
89. Gehrmann, J.; Matsumoto, Y.; Kreutzberg, G. W. Microglia: Intrinsic Immunoeffector Cell of the Brain. Brain Res. Rev. 1995, 20, 269-28.
90. Hofman, F. M.; Hinton, D. R.; K. Johnson; Merrill, J. E. Tumor Necrosis Factor Identified in Multiple Sclerosis Brain. J. Exp. Med. 1989, 170, 607-612.
91. Rogers, J.; Luber-Narod, J.; Styren S. D.; Civin, W. H. Expression of Immune System-associated Antigens by Cells of the Human Central Nervous System: Relationship to the Pathology of Alzheimer's Disease, Neurobiol. Aging 1988, 9, 339-349.
92. McGeer, P. L.; Itagaki, S.; Boyes, B. E.; McGeer, E.G.; Reactive Microglia are Positive for HLA-DR in the Substantia Nigra of Parkinson's and Alzheimer's Disease Brains, Neurology 1988, 38, 1285-1291.
93. Dickson, D. W.; Mattiace, L. A.; Kure, K.; Hutchins, K.; Lyman, W. D.; Brosnan, C. F. Microglia in Human Disease, with an Emphasis on Acquired Immune Deficiency Syndrome. Lab. Invest. 1991, 64, 135-156.
94. Gebicke-Haerter, P. J.; Bauer, J.; Schobert, A.; Northoff, H. Lipopolysaccharide Free Conditions in Primary Astrocyte Cultures Allow Growth and Isolation of Microglia Cells. J. Neurosci. 1989, 9, 183-194.
95. Minghetti, L.; Nicolini, A.; Polazzi, E.; Crüinon, C.; Maclouf, J.; Levi, G. Inducible Nitric Oxide Synthase Expression in Activated rat Microglial Cultures is Down-Regulated by Exogenous Prostaglandin E2 and by Cyclooxygenase Inhibitors, Glia 1997, 19, 152-160.
96. Chao, C. C.; Hu, S.; Molitor, T. W.; Shaskan, E. G.; Peterson, P. K. Activated Microglia Mediate Neuronal Cell Death Injury via a Nitric Oxide Mechanism. J. Immunol. 1992, 149, 2736-2741.
97. Merrill, J. E.; Ignarro, L. J.; Sherman, M. P.; Melinek, J.; Lane, T. E.; Microglial Cell Cytotoxicity of Oligodendrocytes Is Mediated Through Nitric Oxide. J. Immunol. 1993, 151, 2132-2141.
98. Meda, L.; Cassatella, M. A.; Szendrei, G. I.; Otvos, L. Jr.; Baron, P.; Villalba, M.; Ferrari, D.; Rossi, F. Activation of Microglial Cells by β-Amyloid Protein and Interferon-γ. Nature 1995, 374, 647-650.
99. Schafar, A. I. Antiplatelet Therapy. Am. J. Med. 1996, 101, 199-209.
100. http://hsc.virginia.edu/medicine/clinical/pathology/educ/innes/text/nh/function.html
101. Band, N. U.; Wilson, D. B. Normal Platelet Function and Antiplatelet Drugs, ACC Curr. J. Rev. 1999, 13-16
102. Flores, N. A. Platelet Activation during Myocardial Ischaemia: a Contributory Arrhythmogenic Mechanism. Pharmacol. Ther. 1996, 72, 83-108.
103. Gonzalez, E. R. Antiplatelet Therapy in Atherosclerotic Cardiovascular Disease, Clin. Ther. 1998, 20, supplement B,18-41.
104. Mousa, S. A. Antiplatelet Therapies: from Aspirin to GPIIb/IIIa-Receptor Antagonists and beyond. Drug Discovery Today 1999, 4, 552-561.
105. Tromethamine salt: Anderson, B. D.; Conradi, R. A. Predictive Relationships in the Water Solubility of Salts of a Nonsteroidal Anti-inflammatory Drug. J. Pharm. Sci. 1985, 74, 815-820.
106. Gund, P. Evoluation of the Pharmacophore Concept in Pharmaceutical Research, in Pharmacophore Perception, Development, and Use in Drug Design, Guner, O. F. Ed., La Jolla, IUL Biotechnology series 2000, pp3-11.
107. Cohen, N. C.; Blaney, J. M.; Humblet, C.; Gund, P.; Barry, D. C. Molecular Modeling Software and Methods for Medicinal Chemistry. J. Med. Chem. 1990, 33, 883-894.
108. P. W. Sprague, Automated Chemical Hypothesis Generation and Database Searching with Catalyst. Perspect. Drug Discovery Des. 1995, 3, 1-20.
109. Kaminski, J. J.; Rane, D. F.; Snow, M. E.; Weber, L.; Rothofsky, M. L.; Anderson, S. D.; Lin, S. L.; Identification of Novel Farnesyl Protein Transferase Inhibitors Using Three-Dimensional Database Searching Methods. J. Med. Chem. 1997, 40, 4103-4112.
110. Lòpez-Rodrígez, M. L.; Porras, E.; Banhamú, B.; Romas, J. A.; Morcillo, M. J.; Lvandera, J. L. First Pharmacophoric Hypothesis for 5-HT7 Antagonism. Bioorg. Med. Chem. Lett. 2000, 10, 1097-1100.
111. Bremner, J. B.; Coban, B.; Griffith, R.; Groenwoud, K. M.; Yates, B. F. Ligand Design for α-Adrenoceptor Subtype Selective Antagonists. Bioorg. Med. Chem. 2000, 8, 201-214.
112. Palomer, A.; Cabre, F.; Pascual, J.; Campos, J.; Trujillo, M. A.; Entrena, A.; Gallo, M. A.; Garcia, L.; Mauleon, D.; Espinosa, A. Identification of Novel Cyclooxygenase-2 Selective Inhibitors Using Pharmacophore Models. J. Med. Chem. 2002, 45, 1402-1411.
113. http://www.accelrys.com/doc/life/index.html
114. Ngan, V. K.; Bellman, K.; Panda, D.; Hill, B. T.; Jordan, M. A.; Wilson, L. Novel Actions of the Antitumor Drugs Vinflunine and Vinorelbine on Microtubules. Cancer Res. 2000, 60, 5045-5051.
115. Ngan, V. K.; Bellman, K.; Hill, B. T.; Wilson, L.; Jordan, M. A. Mechanism of Mitotic Block and Inhibition of Cell Proliferation by the Semisynthetic Vinca Alkaloids Vinorelbine and Its Newer Derivative Vinflunine. Mol Pharmacol. 2001, 60, 225-232.
116. Fukuoka, K.; Arioka, H.; Iwamoto, Y.; Fukumoto, H.; Kurokawa, H.; Ishida, T.; Tomonari, A.; Suzuki, T.; Usuda, J.; Kanzawa, F.; Saijo, N.; Nishio, K. Mechanism of the Radiosensitization Induced by Vinorelbine in Human Non-small Cell Lung Cancer Cells. Lung Cancer 2001, 34, 451-60.
117. Kanazawa, J.; Morimoto, M.; Ohmori, K. Properties of Antitumor Activity of Vinorelbine Tartrate, a New Vinca Alkaloid Antitumor Agent. Nippon Yakurigaku Zasshi 2000, 116, 215-223.
118. Niitani, H.; Hisakatsu, S. Antimicrotubule Agents. Gan To Kagaku Ryoho. 1993, 2034-2041.
119. Koyanagi, N.; Nagasu, T.; Fujita, F.; Watanabe, T.; Tsukahara, K.; Funahashi, Y.; Fujita, M.; Taguchi, T.; Yoshino, H.; Kitoh, K. In vivo Tumor Growth Inhibition Produced by a Novel Sulfonamide, E7010, against Rodent and Human Tumors. Cancer Res. 1994, 54, 1702-1706.
120. Yoshimatsu, K.; Yamaguchi, A.; Yoshino, H.; Koyanagi, N.; Kitoh, K. Mechanism of Action of E7010, an Orally Active Sulfonamide Antitumor Agent: Inhibition of Mitosis by Binding to the Colchicine Site of Tubulin. Cancer Res. 1997, 57, 3208-3213.
121. Yamamoto, K.; Noda, K.; Yoshimura, A.; Fukuoka, M.; Furuse, K.; Niitani, H. Phase I Study of E7010. Cancer Chemother. Pharmacol. 1998, 42, 127-134.
122. Berridge, M. V.; Tan, A. S. Characterization of the Cellular Reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT): Subcellular Localization, Substrate Dependence, and Involvement of Mitochondrial Electron Transport in MTT Reduction. Arch. Biochem. Biophys. 1993, 303, 474-482.
123. Lopez-Lluch, G.; Buron, M. I.; Alcain, F. J.; Quesada, J. M.; Navas, P. Redox Regulation of cAMP Levels by Ascorbate in 1,25-Dihydroxy-Vitamin D3-Induced Differentiation of HL-60 Cells. Biochem. J. 1998, 331, 21-27.
124. Yoshida, K.; Murohashi, I.; Hirashima, K. p53-Independent Induction of p21 (WAF1/CIP1) During Differentiation of HL-60 Cells by Tumor Necrosis Factor alpha. Int. J. Hematol. 1996, 65, 41-48.
125. J. P. Wang, S. L. Raung, Y. H. Kuo and C. M. Teng, Daphnoretin-induced respiratory burst in rat neutrophils is probably mainly through protein kinase C activation, Eur. J. Pharmacol. 1995, 288, 341-348.
126. Markert, M.; Andrews, P. C.; Babior, B. M. Measurement of O2·－ Production by Human Neutrophils. The Preparation and Assay of NADPH Oxidase-containing Particles from Human Neutrophils. Methods Enzymol. 1984, 105, 358-365.
127. Newby, A. C. Role of Aadenosine Deaminase, Ecto-(5’-nucleo-tidase) and Ecto-(non-specific phosphatase) in Cyanide-Induced Adenosine Monophosphate Catabolism in Rat Polymorphonuclear Leucocytes. Biochem. J. 1980, 186, 907-918.
128. Barrett, A. J. ”A Laboratory Handbook”, Dingle, J. T. ed (Elsevier/North- Holland, Amsterdam) 1972, 118-120.
129. Absolom, D.R. Basic Methods for the Study of Phagocytosis. Methods Enzymol. 1986, 132, 95-179.
130. Wang, J. P.; Raung, S. L.; Hsu, M. F.; Lin, C. N. Inhibition by Gomisin C (a Lignan from Schizandra chinensis) of the Respiratory Burst of Rat Neutrophils. Br. J. Pharmacol. 1994, 113, 945-953.
131. Goldberg, B.; Stern, A. The Role of the Superoxide Anion as a Toxic Species in the Erythrocyte. Arch. Biochem. Biophys. 1977, 178, 218-225.
132. McClain, D. E.; Donlon, M. A.; Chock, S.; Catravas, G. N. The Effect of Calmodulin on Histamine Release in the Rat Peritoneal Mast Cell. Biochem. Biophys. Acta. 1983, 763, 419.
133. Hanahae, T. H. P. Mechanism of Histamine Release from Rat Isolated Peritoneal Mast Cells by Dextran: the Role of Immunglobulin E. Agents Action 1984, 14, 468.
134. Johnson, A. R.; Erdos, E. G. Release of Histamine from Mast Cell by Vasoactive Peptides. Proc. Soc. Exp. Biol. Med. 1973, 142, 1252-1256.
135. Hakanson, R.; Ronnberg, A. L. Improved Fluorometric Assay of Histamine, Antlyt. Biochem. 1974, 60, 560-567.
136. Corradin, S. B.; Manuel, J.; Donini, S. D.; Quattrocchi, E.; RicciardiCastagnoi, P. Inducible Nitric Oxide Synthase Activity of Cloned Murine Microglial Cells. Glia 1993, 7, 255-262.
137. Minghetti, L.; Nicolini, A.; Polazzi, E.; Creminon, C.; Maclouf, J.; Levi, G.; Inducible Nitric Oxide Synthase Expression in Activted Rat Microglial Cultures Is Down-Regulated by Exogenous Prostaglandin E2 and by Cyclooxygenase Inhibitors. Glia 1997, 19, 152-160.
138. Maitou, J.; Komatsu, H.; Ujiie, A.; Hamano, S.; Kubota, T.; Tsuboshima, M.; Eur. J. Pharmacol. 1983, 91, 41-48.
139. (a) Iizuka, K.; Akahane, K.; Momose, D.; Nakazawa, M.; Taniguchi, T.; Kawamura, M.; Ohyama, I.; Iguchi, Y.; Okada, T.; Taniguchi, K.; Miyamoto, T.; Hayashi, M. Highly Selective Inhibitors of Thromboxane Synthetase. 1. Imidazole Derivatives. J. Med. Chem. 1981, 24, 1139-1148. (b) Tanouchi, T.; Kawamura, M.; Ohyama, I.; Kajiwara, I.; Iguchi, Y.; Okada, T.; Miyamoto, T.; Taniguchi, K.; Hayashi, M.; Iizuka, K.; Nakazawa, M. Highly Selective Inhibitors of Thromboxane Synthetase. 2. Pyridine Derivatives. J. Med. Chem. 1981, 24, 1149-1155.
Part II參 考 文 獻
1. J. C. Thresh, Pharm. J., 10, 171 (1879); ibid., 12, 243 (1882).
2. H. Nomura, L. K. Pearson and F. A. Royle, J. Chem. Soc., Ⅲ, 769 (1917).
3. E. K. Nelson, J. Am. Chem. Soc., 39, 1466 (1917).
4. 陰健主編,中藥現代研究與臨床應用, 1, 235-236 (1993).
5. Qirong Huang , Chem. Pharm. Bull., 39, 397-399 (1991).
6. A. Lapworth and F. H. Wykes, J. Chem. Soc., Ⅲ, 790 (1917).
7. H. Nomura and S. Tsurumic, Proc. Imp. Acad. Japan, 3, 159 (1927).
8. E. Hirao, T. Toyama, A. Takahata and B. Yasui, Chem. Pharm. Bull. Japan, 20, 2287 (1972).
9. K. Banno and T. Mukaiyama, Bull. Chem. Soc. Japan, 49, 1453 (1976).
10. P. Denniff and D. A. Whiting, J. Chem. Soc. Chem. Comm., 712-713 (1976).
11. P. Denniff, I. Macleod and D. A. Whiting, J. Chem. Soc. Perkin Trans. I, 82-87 (1981).
12. S. J. Sheu, Y. T. Chang, Y. P. Chen and H. Y. Hsu, J. Taiwan Pharm. Assoc., 31, 40-45 (1979).
13. I. Kazuhito, O. Hiroyuki and S. Masaki, Jpn. Kokai Tokkyo Koho JP 03 90,021 9pp. (1991).
14. D. Enders, H. Eichenauer and R. Pieter, Chem. Ber. 112, 3703-3714 (1979).
15. R. Annunziata, Synthesis, 702-703 (1984).
16. M. Cinquini, F. Cozzi and A. Gilardi, J. Chem. Soc. Commun., 551-552 (1984).
17. T. L. Gall, J. P. Lellouche and J. P. Beaucourt, Tetrahedron Lett., 30, 6521-6524 (1989).
18.G. Solladie and Z. C. Chewki, J. Org. Chem., 58, 2181-2185 (1993).
19.G. Solladie and N. Chiatou, Bull. Soc. Chim. Fr., 131, 575-578 (1994).
20.O. Hiroyuku, S. Yoshiyuki, E. Isamu, U. Hideto and I. Masashi, PCT Int. Appl. WO 89 08,093 34pp. (1989).
21.W. Tang and G. Eisenbrand, Chinese Drugs of Plant, Springer Verlag, Berlin, 1011 (1992).
22.J. Yamahara, S. Hatakeyama, K. Taniguchi, M. Kawamura and M. Yoshikawa, Yakugaku Zasshi, 112, 645-655 (1992).
23.M. Yoshikama, S. Hatakeyama, K. Taniguchi, H. Matuda and J. Yamahara, Chem. Pharm. Bull. Japan, 40, 2239-2241 (1992).
24.劉慶增, 中藥藥理與臨床, 4, 50 (1988).
25.J. Yamahara, J. Ethnopharmacology., 13, 217 (1985).
26.H. Hikino, Y. Kiso, N. Kato, Y. Hamada, Y. Shioiri, R. Aiyama, H. Itokawa, F. Kiuchi and U. Sankawa, J. Ethnopharmacol., 14, 31 (1985).
27.山上一香, 醫學中央雜誌, 112, 669 (1954).
28.周濟桂, 天津醫學雜誌, 2, 131 (1960).
29.油田正對, 國外醫學中醫中藥雜誌, 5, 49 (1981).
30.油田正對, 國外醫學中醫中藥分冊, 3, 162 (1982).
31.Q. Huang, H. Matsuda and K. Tamai, Yakugaku Zasshi, 110, 936-942 (1990).
32.N. Shoji, A. Iwasa, T. Takemoto, Y. Ishida and Y. Ohizumi, J. Pharm. Sci., 71, 1174-1175 (1982).
33.(a) M. Kobayashi, N. Shoji and Y. Ohizumi, Biochimica et Biophysica Acta, 903, 96 (1987). (b) Y. Ohizumi, S. Sasaki, K. Shibusawa, K. Ishikawa and F. Ikemoto, Chem. Pharm. Bull., 19, 1377 (1996).
34.笠原正義, 生藥學雜誌（日）, 37, 73 (1983).
35.K. Endo, E. Kanno and Y. Oshima, Phytochemistry, 29, 797-799 (1990).
36.C. O. Adewunmi, B. O. Oguntimein and P. Furu, Planta Med., 56, 374-376 (1990).
37.F. Kiuchi, M. Shibuya and U. Sankawa, Chem. Pharm. Bull., 30, 754-757 (1982).
38.Y. Y. Lai, L. J. Huang, H. C. Lin, T. S. Wu, C. M. Teng and S. C. Kuo, Chin. Pharm. J. (2002). (Accepted)
39.Y. Y. Lai, L. J. Huang, H. C. Lin, T. S. Wu, C. M. Teng and S. C. Kuo, Chin. Pharm. J., 54, 41-52 (2002).
40. http://www.micro.unsw.edu.au/!THEHELI.COP/helihome.html
41. (a) NIH Consensus Conference: Helicobacter pylori in Peptic Ulcer Disease. JAMA.,
272, 65-69 (1994). (b) Consensus Satement: Medical Treatment of Peptic Ulcer Disease. JAMA., 272, 622-629 (1996). (c) The European Helicbacter pylori Study Group (EHPSG). Current European concepts in the management of Helicobacter pylori infection. The Masstricht Consensus Report. Gut, 41, 8-13 (1997). (d) Helicobacter pylori consensus. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J. Gastroenterol & Hepatol., 13, 1-12 (1998).
42. http://tw.news.yahoo.com/2002/04/10/leisure/ftv/3171727.html
43. E. Nogales, S. G. Wolf and K. H. Downing, Nature, 391, 199-203 (1998).
44. F. M. Uckun,. C. Mao, A. O. Vassilev, C. S. Navara, R. K. S. Narla and S. T. Jan, Bioorganic & Medicinal Chemistry Letters, 10, 1015-1018 (2000).
45. S. T. Jan, C. Mao, A. O. Vassilev, C. S. Navara and F. M. Uckun, Bioorganic & Medicinal Chemistry Letters, 10, 1193-1197 (2000).
46. S. Masao, M. Michio, K. Ichiro and S. Toshimitsu, Jpn. Kokai Tokkyo Koho JP 62, 249, 918 7pp. (1987).
47. G. Lopez-Lluch, M. I. Buron, F. J. Alcain, J. M. Quesada and P. Navas, Biochem. J. 331, 21-27 (1998).
48. Q. He and D. Jiang, Leuk. Res., 23, 369-372 (1999).
49. M. V. Berridge and A. S. Tan, Arch. Biochem. Biophys. 303, 474-482 (1993).
|